Cubist Pharmaceuticals (CBST) 63.95 $CBST
Cubist to Announce First Quarter 2014 Financial Results on Tuesday, April 22, 2014
Business Wire - Tue Apr 15, 7:00AM CDT
Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) will issue its first quarter 2014 financial results at 4:00 p.m. ET on Tuesday, April 22, 2014. In connection with this announcement, Cubist will host a conference call and live audio webcast presentation at 5:00 p.m. ET that same day to discuss its first quarter financial results, business activities, and financial outlook.
Cubist Pharmaceuticals Set to Possibly Rebound After Yesterday's Selloff of 2.42%
Comtex SmarTrend(R) - Mon Apr 14, 4:46PM CDT
Cubist Pharmaceuticals (NASDAQ:CBST) traded in a range yesterday that spanned from a low of $60.38 to a high of $64.73. Yesterday, the shares fell 2.4%, which took the trading range below the 3-day low of $63.01 on volume of 1.5 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Cubist Pharmaceuticals Down 12.8% Since SmarTrend Downtrend Call (CBST)
Comtex SmarTrend(R) - Mon Apr 14, 9:21AM CDT
SmarTrend identified a Downtrend for Cubist Pharmaceuticals (NASDAQ:CBST) on March 24th, 2014 at $73.60. In approximately 3 weeks, Cubist Pharmaceuticals has returned 12.75% as of today's recent price of $64.21.
Will Johnson & Johnson (JNJ) Miss This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 14, 9:00AM CDT
Johnson & Johnson has an Earnings ESP of 0.00% with a Zacks Rank #2 (Buy).
Biotech Stock Roundup: MannKind Soars on Panel Vote, Halozyme Plunges on Safety Concerns - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Apr 09, 11:46AM CDT
Last week saw a couple of positive FDA panel votes as well as some disappointing data on experimental drugs.
Cubist Pharmaceuticals (CBST) Marked As Today's Roof Leaker Stock
at The Street - Tue Apr 08, 9:41AM CDT
Trade-Ideas LLC identified Cubist Pharmaceuticals (CBST) as a "roof leaker" (crossing below the 200-day simple moving average on higher than normal relative volume) candidate
Pfizer Blockbuster Zyvox Under Attack
Cory Renauer, The Motley Fool - Motley Fool - Tue Apr 08, 8:30AM CDT
Incoming competition for Pfizer 's $1.4 billion Zyvox market is threatening on multiple fronts. With several important revenue streams drying up, this one has become more important than ever to the drug company. Recently, an FDA advisory...
What's Next for Cubist Pharmaceuticals Inc. and Durata Therapeutics, Inc.?
Amy Ho, The Motley Fool - Motley Fool - Fri Apr 04, 5:30PM CDT
Cubist Pharmaceuticals and Durata Therapeutics both won this week with nods by the FDA's advisory panels on each company's antibacterial agents. In two unanimous votes, the FDA panels agreed on the safety and efficacy of Cubist's tedizolid and...
Biotech Stock Roundup: Biogen Drug Approved, Exelixis Tumbles on Study Update - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Apr 02, 9:43AM CDT
Biotech companies continued to witness a decline in share prices last week.
Tetraphase Antibiotic Nearing Key Tolerability Test
at The Street - Wed Apr 02, 7:00AM CDT
The lead-in phase of a phase III study will tell us a lot about whether Tetraphase's eravacycline antibiotic can be administered orally.
Cubist Rises on Favorable FDA Panel View - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 01, 10:30AM CDT
An advisory panel recommended the approval of Sivextro in the U.S.
Cubist Appoints Robert J. Perez to Board of Directors
Business Wire - Tue Apr 01, 7:02AM CDT
Cubist (NASDAQ: CBST) today announced the appointment of Robert J. Perez to its Board of Directors. Since 2012, Mr. Perez has served as Cubist's President and Chief Operating Officer (COO). The Company also announced that in accordance with its Corporate Governance Guidelines regarding term limits, three long-serving Directors, Dr. Michael B. Wood, Dr. Martin Rosenberg, and J. Matthew Singleton, each submitted a revocable resignation letter thereby notifying the Company of their intent to retire from the Board effective at the Company's 2014 Annual Meeting of Stockholders.
FDA Advisory Committee Unanimously Recommends Approval of Cubist's SIVEXTRO(TM) (Tedizolid Phosphate) as Treatment for Serious Skin Infections
Business Wire - Mon Mar 31, 12:40PM CDT
Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) announced today that the U.S. Food and Drug Administration (FDA) Anti-Infective Drugs Advisory Committee (AIDAC) voted to recommend approval of Cubist's investigational antibiotic SIVEXTRO(TM) (tedizolid phosphate). In the unanimous 14 - 0 decision, the AIDAC found that substantial evidence of the safety and effectiveness of SIVEXTRO for the treatment of acute bacterial skin and skin structure infections (ABSSSI) was provided.
First Week of CBST November 22nd Options Trading
DividendChannel.com - Wed Mar 26, 11:27AM CDT
Investors in Cubist Pharmaceuticals Inc. saw new options become available this week, for the November 22nd expiration.
Biotech Stock Roundup: GILD Letter Triggers Major Selloff - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Mar 26, 9:13AM CDT
Are the good days over for the biotech sector or is this just a correction?
Pharma & Biotech Stock Outlook - March 2014 - Zacks Analyst Interviews
Arpita Dutt - Zacks Investment Research - Wed Mar 26, 1:17AM CDT
Pharma & Biotech Stock Outlook - March 2014 - Zacks Analyst Interviews
Pharma & Biotech Stock Outlook - March 2014 - Industry Outlook
Arpita Dutt - Zacks Investment Research - Wed Mar 26, 1:17AM CDT
Pharma & Biotech Stock Outlook - March 2014 - Industry Outlook
Tetraphase's Eravacycline Holds Promise - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 25, 10:30AM CDT
Tetraphase is working hard to develop its pipeline.
3 Upcoming FDA Meetings You Should be Watching
Sean Williams, The Motley Fool - Motley Fool - Fri Mar 21, 1:05PM CDT
Just because we're out of earnings season doesn't mean there aren't big data-driven events happening in the health care sector. Between now and the end of the month there are three Food and Drug Administration panel meetings that are bound to...
Better Buy: Cubist Pharmaceuticals, Inc. vs. Durata Therapeutics, Inc.
George Budwell, The Motley Fool - Motley Fool - Thu Mar 20, 8:30AM CDT
Regulatory decisions are generally chaotic events for biotech companies, especially when they involve a lead clinical candidate. Approvals can send shares soaring as the market prices in future revenue, whereas a rejection nearly always results in a...
Cubist to Announce First Quarter 2014 Financial Results on Tuesday, April 22, 2014
Business Wire - Tue Apr 15, 7:00AM CDT
Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) will issue its first quarter 2014 financial results at 4:00 p.m. ET on Tuesday, April 22, 2014. In connection with this announcement, Cubist will host a conference call and live audio webcast presentation at 5:00 p.m. ET that same day to discuss its first quarter financial results, business activities, and financial outlook.
Cubist Pharmaceuticals Set to Possibly Rebound After Yesterday's Selloff of 2.42%
Comtex SmarTrend(R) - Mon Apr 14, 4:46PM CDT
Cubist Pharmaceuticals (NASDAQ:CBST) traded in a range yesterday that spanned from a low of $60.38 to a high of $64.73. Yesterday, the shares fell 2.4%, which took the trading range below the 3-day low of $63.01 on volume of 1.5 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Cubist Pharmaceuticals Down 12.8% Since SmarTrend Downtrend Call (CBST)
Comtex SmarTrend(R) - Mon Apr 14, 9:21AM CDT
SmarTrend identified a Downtrend for Cubist Pharmaceuticals (NASDAQ:CBST) on March 24th, 2014 at $73.60. In approximately 3 weeks, Cubist Pharmaceuticals has returned 12.75% as of today's recent price of $64.21.
Will Johnson & Johnson (JNJ) Miss This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 14, 9:00AM CDT
Johnson & Johnson has an Earnings ESP of 0.00% with a Zacks Rank #2 (Buy).
Biotech Stock Roundup: MannKind Soars on Panel Vote, Halozyme Plunges on Safety Concerns - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Apr 09, 11:46AM CDT
Last week saw a couple of positive FDA panel votes as well as some disappointing data on experimental drugs.
Cubist Pharmaceuticals (CBST) Marked As Today's Roof Leaker Stock
at The Street - Tue Apr 08, 9:41AM CDT
Trade-Ideas LLC identified Cubist Pharmaceuticals (CBST) as a "roof leaker" (crossing below the 200-day simple moving average on higher than normal relative volume) candidate
Pfizer Blockbuster Zyvox Under Attack
Cory Renauer, The Motley Fool - Motley Fool - Tue Apr 08, 8:30AM CDT
Incoming competition for Pfizer 's $1.4 billion Zyvox market is threatening on multiple fronts. With several important revenue streams drying up, this one has become more important than ever to the drug company. Recently, an FDA advisory...
What's Next for Cubist Pharmaceuticals Inc. and Durata Therapeutics, Inc.?
Amy Ho, The Motley Fool - Motley Fool - Fri Apr 04, 5:30PM CDT
Cubist Pharmaceuticals and Durata Therapeutics both won this week with nods by the FDA's advisory panels on each company's antibacterial agents. In two unanimous votes, the FDA panels agreed on the safety and efficacy of Cubist's tedizolid and...
Biotech Stock Roundup: Biogen Drug Approved, Exelixis Tumbles on Study Update - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Apr 02, 9:43AM CDT
Biotech companies continued to witness a decline in share prices last week.
Tetraphase Antibiotic Nearing Key Tolerability Test
at The Street - Wed Apr 02, 7:00AM CDT
The lead-in phase of a phase III study will tell us a lot about whether Tetraphase's eravacycline antibiotic can be administered orally.
Cubist Rises on Favorable FDA Panel View - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 01, 10:30AM CDT
An advisory panel recommended the approval of Sivextro in the U.S.
Cubist Appoints Robert J. Perez to Board of Directors
Business Wire - Tue Apr 01, 7:02AM CDT
Cubist (NASDAQ: CBST) today announced the appointment of Robert J. Perez to its Board of Directors. Since 2012, Mr. Perez has served as Cubist's President and Chief Operating Officer (COO). The Company also announced that in accordance with its Corporate Governance Guidelines regarding term limits, three long-serving Directors, Dr. Michael B. Wood, Dr. Martin Rosenberg, and J. Matthew Singleton, each submitted a revocable resignation letter thereby notifying the Company of their intent to retire from the Board effective at the Company's 2014 Annual Meeting of Stockholders.
FDA Advisory Committee Unanimously Recommends Approval of Cubist's SIVEXTRO(TM) (Tedizolid Phosphate) as Treatment for Serious Skin Infections
Business Wire - Mon Mar 31, 12:40PM CDT
Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) announced today that the U.S. Food and Drug Administration (FDA) Anti-Infective Drugs Advisory Committee (AIDAC) voted to recommend approval of Cubist's investigational antibiotic SIVEXTRO(TM) (tedizolid phosphate). In the unanimous 14 - 0 decision, the AIDAC found that substantial evidence of the safety and effectiveness of SIVEXTRO for the treatment of acute bacterial skin and skin structure infections (ABSSSI) was provided.
First Week of CBST November 22nd Options Trading
DividendChannel.com - Wed Mar 26, 11:27AM CDT
Investors in Cubist Pharmaceuticals Inc. saw new options become available this week, for the November 22nd expiration.
Biotech Stock Roundup: GILD Letter Triggers Major Selloff - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Mar 26, 9:13AM CDT
Are the good days over for the biotech sector or is this just a correction?
Pharma & Biotech Stock Outlook - March 2014 - Zacks Analyst Interviews
Arpita Dutt - Zacks Investment Research - Wed Mar 26, 1:17AM CDT
Pharma & Biotech Stock Outlook - March 2014 - Zacks Analyst Interviews
Pharma & Biotech Stock Outlook - March 2014 - Industry Outlook
Arpita Dutt - Zacks Investment Research - Wed Mar 26, 1:17AM CDT
Pharma & Biotech Stock Outlook - March 2014 - Industry Outlook
Tetraphase's Eravacycline Holds Promise - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Mar 25, 10:30AM CDT
Tetraphase is working hard to develop its pipeline.
3 Upcoming FDA Meetings You Should be Watching
Sean Williams, The Motley Fool - Motley Fool - Fri Mar 21, 1:05PM CDT
Just because we're out of earnings season doesn't mean there aren't big data-driven events happening in the health care sector. Between now and the end of the month there are three Food and Drug Administration panel meetings that are bound to...
Better Buy: Cubist Pharmaceuticals, Inc. vs. Durata Therapeutics, Inc.
George Budwell, The Motley Fool - Motley Fool - Thu Mar 20, 8:30AM CDT
Regulatory decisions are generally chaotic events for biotech companies, especially when they involve a lead clinical candidate. Approvals can send shares soaring as the market prices in future revenue, whereas a rejection nearly always results in a...
